COMPOUND FOR PREVENTING OR TREATING DIABETES

• Main Author: KIM, Yi Rang
• Format: Patent
• Language: English; French; Korean
• Published: 13.10.2022
• Subjects: FOODS OR FOODSTUFFS; FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BYSUBCLASSES A23B - A23J; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OFNUTRITIVE QUALITIES, PHYSICAL TREATMENT; THEIR TREATMENT, NOT COVERED BY OTHER CLASSES

The present invention relates to a use of (R)-4-{(R)-1-[7-(3,4,5-trimethoxy-phenyl)-[1,6] naphthyridine-5-yloxy]-ethyl}pyrrolidine-2-one for treating diabetes. According to the present invention, (R)-4-{(R)-1-[7-(3,4,5-trimethoxy-phenyl)-[1,6] naphthyridine-5-yloxy]-ethyl}pyrrolidine-2-one of the present invention alleviates clinical symptoms of diabetes, reduces blood sugar, reduces blood glucose concentrations and insulin-resistance and reduces liver and kidney damage in an animal model of insulin-resistant diabetes, and thus can be effectively used for preventing or treating diabetes, especially insulin-resistant diabetes. La présente invention concerne une utilisation de (R)-4-{(R)-1-[7-(3,4,5-triméthoxy-phényle)-[1,6]naphthyridine-5-yloxy]-éthyl}pyrrolidine-2-one pour le traitement du diabète. Selon la présente invention, (R)-4-{(R)-1-[7-(3,4,5-triméthoxy-phényle)-[1,6]naphthyridine-5-yloxy]-éthyl}pyrrolidine-2-one atténue les symptômes cliniques du diabète, réduit la glycémie, réduit les concentrations de glucose dans le sang ainsi que la résistance à l'insuline, et réduit les lésions hépatiques et rénales dans un modèle animal atteint de diabète résistant à l'insuline, et peut ainsi être efficacement utilisé pour prévenir ou traiter le diabète, en particulier le diabète résistant à l'insuline. 본 발명은 (R)-4-{(R)-1-[7-(3,4,5-트리메톡시-페닐)-[1,6] 나프티리딘-5-일옥시]-에틸}피롤리딘-2-온의 당뇨병 치료 용도에 관한 것으로, 본 발명에 따르면, 본 발명의 (R)-4-{(R)-1-[7-(3,4,5-트리메톡시-페닐)-[1,6] 나프티리딘-5-일옥시]-에틸}피롤리딘-2-온는 인슐린 저항성 당뇨병 동물모델에서 당뇨병 임상 증상을 개선시켰으며, 혈당을 감소시키고, 혈액 내 글루코스의 농도 및 인슐린 저항성을 감소시켰으며, 간 및 신장 손상을 감소시켰으므로, 이를 당뇨병, 특히, 인슐린 저항성 당뇨병의 예방 또는 치료 용도로 유용하게 활용할 수 있다.